louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01300442: Effects of Transcutaneous Electrical Diaphragmatic Stimulation on Respiratory Variables in COPD Patients
Official title: Fundamentation of TEDS Protocol in Healthy Subjects and Its Application in COPD Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: COPD
Keywords: chronic obstructive pulmonary disease
diaphragm
electrical stimulation
pulmonary rehabilitation
Lead sponsor: Universidade Federal de Sao Carlos
Sponsor class: OTHER
Collaborators: name: Conselho Nacional de Desenvolvimento Científico e Tecnológico
First posted: 2011-02-21
Enrollment: 30
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Transcutaneous electrical diaphragmatic stimulation (TEDS) has been used to improve respiratory muscle strength in patients with respiratory muscles weakness. However, this physiotherapeutic resource has not been studied in chronic obstructive pulmonary disease (COPD) yet. The objective of this study is to evaluate the respiratory pattern during the session of TEDS besides its effect in respiratory muscle strength and in spirometric variables as much healthy patients as in COPD patients. Methods: healthy and COPD patients are selected and submitted to TEDS treatment. The plethysmographic analysis (LifeShirt System - VivoMetric), respiratory muscle strength and spirometry will be made. The hypothesis is that the TEDS can helps COPD patients that shows respiratory muscle weakness.


Eligibility criteria: Inclusion Criteria:

* Patients with stable COPD (diagnosed by accepted criteria)
* Healthy patients

Exclusion Criteria:

* FOR THE COPD PATIENTS:
* Over 80 years of age
* History of recent exacerbation
* Patients with pacemakers
* Uncontrolled arterial hypertension
* Requiring home oxygen therapy.
* FOR THE HEALTHY PATIENTS:
* Pulmonary diseases
* Cardiovascular diseases
* Orthopedic diseases
* Neurologic diseases.

Primary outcomes:
measure: Respiratory muscle strength and spirometry
timeFrame: 06 weeks
Secondary outcomes:
measure: Respiratory pattern
timeFrame: During the session of transcutaneous electrical diaphragmatic stimulation
Other outcomes:
Locations:
city: São Carlos
country: Brazil
facility: UFSCar
state: São Paulo
Study officials:
affiliation: UFSCar
name: Dirceu Costa, PhD
role: STUDY_DIRECTOR
References:
citation: Cancelliero-Gaiad KM, Ike D, Pantoni CB, Mendes RG, Borghi-Silva A, Costa D. Acute effects of transcutaneous electrical diaphragmatic stimulation on respiratory pattern in COPD patients: cross-sectional and comparative clinical trial. Braz J Phys Ther. 2013 Nov-Dec;17(6):547-55. doi: 10.1590/S1413-35552012005000121. Epub 2013 Nov 14.
Clinical trial NCT00554970: A Study of 2 Doses of MAP0010 in Adult Asthmatics
Official title: A Randomized, Open Label, Active-Controlled, 4-Treatment, 2-Period, 2 Parallel Block Crossover Pharmacokinetic and Safety Study of 2 Doses of MAP0010 in Adult Asthmatics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Asthma
Keywords: Adult Asthmatics
Lead sponsor: Allergan
Sponsor class: INDUSTRY
Collaborators: name: MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
First posted: 2007-11-07
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.


Eligibility criteria: Inclusion Criteria:

* Male or female adult asthmatics with mild to moderate persistent asthma.
* 18 to 45 (up to the 46th birthday) years of age.
* Documented diagnosis of asthma at least 3 months prior to Visit 1, per NIH/NHLBI, EPR-3 criteria.
* Able to withhold short-acting bronchodilators (e.g., albuterol or ipratropium bromide) for at least 4 hours prior to clinic visits.
* Baseline FEV1 greater than or equal to 50% of predicted normal.

Exclusion Criteria:

* Any other significant illness/abnormality
* A history of upper or lower respiratory tract infection within 2 weeks
* A history of acute or severe asthma attack requiring ICU admission or ventilatory support.

Primary outcomes:
measure: Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
timeFrame: Day 1 hour 12
measure: Cmax of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
timeFrame: Day 8 hour 12
measure: AUC(0-inf) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
timeFrame: Day 1 hour 12
measure: AUC(0-inf) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
timeFrame: Day 8 hour 12
measure: Half-life (t1/2) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
timeFrame: Day 1 hour 12
measure: Half-life (t1/2) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
timeFrame: Day 8 hour 12
Secondary outcomes:
Other outcomes:
Locations:
city: Long Beach
country: United States
facility: West Coast Clinical Trials Phase 2-4, LLC
state: California
Study officials:
affiliation: MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01494870: Management of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Coronary Syndrome
Keywords: acute coronary syndrome
percutaneous coronary intervention
left bundle branch block
Lead sponsor: Samara Regional Cardiology Dispensary
Sponsor class: OTHER
First posted: 2011-12-19
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to propose new treatment algorithm (strategy) for patients with Acute Coronary Syndrome (ACS) and left bundle-branch block (LBBB).

Detailed description: Current recommendations on the treatment of acute coronary syndrome (ACS) dictate urgent reperfusion therapy in the case of evolving myocardial infarction with ST-segment elevation (STEMI). Optimal use of PCI (preferably) or thrombolysis in this situation requires a rapid and correct diagnosis.

According to the ESC'2008 and ACC/AHA'2009 focused update guidelines patients admitted to the hospital within 12 hours after the onset of chest pain with new (or presumably new) left bundle-branch block (LBBB) should be treated like patients having STEMI (class I, level A). However, it is well-known that in patients with concomitant LBBB, the ECG manifestations of acute myocardial injury may be masked.

ACS may occur in a patient with "true old" LBBB (when doctor has/has not an ability to compare the new ECG with the previous one) or (presumably) new LBBB.

There is a high risk of non receiving appropriate therapy or of receiving inappropriate therapy (thrombolysis instead of LMWH/UFH/fondaparinux).

Eligibility criteria: Inclusion Criteria:

* Age 18 - 75 years
* Ischemic discomfort (ie, ischemic chest pain or equivalent) at rest ≥20 minutes within previous 24 hours.
* Any (new, presumably new, or old) LBBB on the prehospital (ambulance) or admission ECG.
* Urgent coronary angiography (followed, when indicated, by PCI), ideally within 90 minutes after admission

Exclusion Criteria:

* all-comers design

Primary outcomes:
measure: mortality
timeFrame: 30 days
Secondary outcomes:
measure: Number of participants survived
timeFrame: 1 year
Other outcomes:
Locations:
city: Samara
country: Russian Federation
facility: Samara Regional Cardiology Dispansery
Study officials:
References:
Clinical trial NCT01080170: The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: Aromatase Inhibitor
Anastrazole
Arimidex
Heart disease
Lipids
Body composition
Breast cancer.
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: National Center for Research Resources (NCRR)
First posted: 2010-03-03
Enrollment: 20
Sex: FEMALE
Minimum age (years): 60
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Breast cancer patients will be recruited via the Magee Breast Cancer Program of the Cancer Center at the University of Pittsburgh Medical Center. Healthy controls will be recruited via registries.

Brief summary: This study explores how aromatase inhibitor therapy affects risk factors for heart disease in postmenopausal women with breast cancer.


Eligibility criteria: Inclusion Criteria:

* Ambulatory women (aged 60-75), with a new diagnosis of nonmetastatic, hormone-receptor positive breast cancer, having undergone lumpectomy. They will not need chemotherapy and will have been prescribed but not yet started anastrazole. All will need a course of radiation therapy as part of usual care. Participants are instructed not to change their physical activity or eating habits over the period of the study.

Comparisons are:

* Identical to the cases except they are hormone-receptor negative and don't need hormonal therapy.
* Healthy controls.

Exclusion Criteria:

* Nicotine usage
* Metastatic breast cancer
* Need for chemotherapy
* AI other than anastrazole
* Usage of steroids (equivalent of equal then or more than 7.5 mg prednisone x 3 months)
* Clinically significant abnormality of thyroid function
* Treatment with gonadal hormone replacement therapy within last 3 years
* Status post unilateral/bilateral surgical oophorectomy
* Having experienced a medical event, which may confound study outcomes \[e.g. heart attack, stroke, cancer (metastatic or newly diagnosed within last 5 years, except for non-melanoma skin cancer and breast), lupus, rheumatoid arthritis, chronic inflammatory disease\]
* Medication-dependent diabetes mellitus or hypercholesterolemia.
* Gastric surgery
* Weight loss medication (prescription or over the counter)

Primary outcomes:
measure: Body Composition
timeFrame: 12 months
Secondary outcomes:
measure: Lipids
timeFrame: 12 months
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh, Department of Medicine.
state: Pennsylvania
Study officials:
References:
Clinical trial NCT04353570: Psychological Impact of Confinement on the Adult
Official title: Psychological Impact of Confinement on the Adult Population Followed in Outpatient Psychiatry at EPS Ville Evrard: Three-month Longitudinal Clinical Evaluation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Identify the Psychological Impact of Containment
Lead sponsor: Centre hospitalier de Ville-Evrard, France
Sponsor class: OTHER
First posted: 2020-04-20
Enrollment: 2100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patient followed in outpatient psychiatry at EPS Ville Evrard

Brief summary: This clinical interview is made to allow a clinical follow-up of the patients followed in psychiatry of the EPS Ville-Evrard establishment in a simple way and in a secure medical framework during the period of the epidemic and the confinement from March 30 to June 30, 2020.


Eligibility criteria: Inclusion Criteria:

Adult patient followed in outpatient psychiatry at EPS Ville Evrard and agrees to participate -

Exclusion Criteria:

Adult patient followed in outpatient psychiatry at EPS Ville Evrard and does not wish to participate

-

Primary outcomes:
measure: Depression MINI DIAG and Anxiety questionnaire and the The Global Performance Rating Scale and CGI-truth
timeFrame: three month
Secondary outcomes:
Other outcomes:
Locations:
city: Neuilly Sur Marne
country: France
facility: Unité de recherche clinique
state: Île De France
Study officials:
References:
Clinical trial NCT00328770: De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Official title: De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Liver Carcinoma
Keywords: liver transplant
hepatocellular carcinoma
sirolimus
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2006-05-22
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.

Detailed description: A total of 70 patients with HCC (mean age: 54.6 years, female/male: 12/58) received a liver transplant and were included in the study. Immunosuppression included de novo sirolimus, low-dose calcineurin inhibitor for 6 to 12 months, with short-course (3 months) or no steroids.

Eligibility criteria: Inclusion Criteria:

* Adult patients with hepatocellular (HCC) carcinoma receiving liver transplant

Exclusion criteria:

* Patients less than 18 years of age

Primary outcomes:
measure: Percentage of Participants Surviving at One and Four Years After Liver Transplant
timeFrame: 1 & 4 years
measure: Percentage of Participants Surviving With no Evidence of Recurrent Tumor at One and Four Years After Liver Transplant
timeFrame: 1 and 4 years
Secondary outcomes:
measure: Sirolimus Toxicity/Intolerance
timeFrame: 1 year
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
Study officials:
affiliation: University of Alberta
name: Norman M Kneteman, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009 Feb;9(2):247-61. doi: 10.1586/14737140.9.2.247.
Clinical trial NCT03062670: Team-Based Delivery of Care in Outpatient Settings
Official title: Team-Based Delivery of Care in Outpatient Settings: An Experimental Investigation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Disease
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2017-02-23
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Through this research we intend to evaluate whether a team-based care delivery approach using daily huddles is effective in improving caregiver and patient outcomes in primary care setting. This approach is expected to not only lead to effective primary care delivery outcomes, but also result in greater team morale, reduced burnout, and a higher rate of innovation.


Eligibility criteria: Inclusion Criteria:

* 18 year old adult
* member of Mayo care team in the Midwest

Exclusion Criteria:

-Unable to provide consent

Primary outcomes:
measure: Change in team cohesion
timeFrame: Change from baseline to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Albert Lea
country: United States
facility: Mayo Clinic Health System in Albert Lea
state: Minnesota
city: Austin
country: United States
facility: Mayo Clinic Health System in Austin
state: Minnesota
city: Cannon Falls
country: United States
facility: Mayo Clinic Health System in Cannon Falls
state: Minnesota
city: Lake City
country: United States
facility: Mayo Clinic Health System in Lake City
state: Minnesota
city: Mankato
country: United States
facility: Mayo Clinic Health System in Mankato
state: Minnesota
city: Owatonna
country: United States
facility: Mayo Clinic Health System in Owatonna
state: Minnesota
city: Red Wing
country: United States
facility: Mayo Clinic Health System in Red Wing
state: Minnesota
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
city: Eau Claire
country: United States
facility: Mayo Clinic Health System in Eau Claire Clinic
state: Wisconsin
city: La Crosse
country: United States
facility: Mayo Clinic Health System - Franciscan Healthcare
state: Wisconsin
Study officials:
affiliation: Mayo Clinic
name: David R Rushlow, MD
role: STUDY_DIRECTOR
References:
citation: Lampman MA, Chandrasekaran A, Branda ME, Tumerman MD, Ward P, Staats B, Johnson T, Giblon R, Shah ND, Rushlow DR. Optimizing Huddle Engagement Through Leadership and Problem Solving Within Primary Care: Results from a Cluster-Randomized Trial. J Gen Intern Med. 2021 Aug;36(8):2292-2299. doi: 10.1007/s11606-020-06487-6. Epub 2021 Jan 26.
citation: Branda ME, Chandrasekaran A, Tumerman MD, Shah ND, Ward P, Staats BR, Lewis TM, Olson DK, Giblon R, Lampman MA, Rushlow DR. Optimizing huddle engagement through leadership and problem-solving within primary care: A study protocol for a cluster randomized trial. Trials. 2018 Oct 4;19(1):536. doi: 10.1186/s13063-018-2847-5.
Clinical trial NCT00213070: Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Keywords: alpha-glucosidase inhibitor,Insulin
Lead sponsor: Sanwa Kagaku Kenkyusho Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2005-09-21
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus with treated insulin.


Eligibility criteria: Inclusion Criteria:

* Type2 diabetes
* Criteria of postprandial plasma glucose and HbA1c are met

Exclusion Criteria:

* Type1 diabetes
* Patients with antidiabetic drugs
* The other exclusion criteria are met

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Aichi
country: Japan
city: Chiba
country: Japan
city: Fukuoka
country: Japan
city: Gifu
country: Japan
city: Gunma
country: Japan
city: Hokkaido
country: Japan
city: Ibaraki
country: Japan
city: Kagoshima
country: Japan
city: Kanagawa
country: Japan
city: Kumamoto
country: Japan
city: Miyazaki
country: Japan
city: Oita
country: Japan
city: Okinawa
country: Japan
city: Saitama
country: Japan
city: Shiga
country: Japan
city: Tokyo
country: Japan
Study officials:
affiliation: Sanwa Kagaku Kenkyusho Co., Ltd.
name: Clinical Promotion Group
role: STUDY_DIRECTOR
References:
Clinical trial NCT03626870: Effects of Resistin on Neutrophil Function
Official title: Effects of Resistin on Neutrophil Function
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Inflammation
Lead sponsor: Milton S. Hershey Medical Center
Sponsor class: OTHER
First posted: 2018-08-13
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all healthy volunteer adults

Brief summary: To assess the effect of resistin on neutrophil migration and intracellular bacterial killing


Eligibility criteria: Inclusion criteria:

* age ≥ 18
* gender: male or female

Exclusion Criteria

* Adults who are unable to provide informed consent themselves
* History of chronic kidney disease as defined by estimated glomerular filtration rate (GFR) \<60 ml/min prior to cardiogenic shock
* Patients with hematologic malignancies
* Pregnant women
* Patient/surrogate is not fluent in English
* Long-term immunosuppressive therapy
* Prisoner
* Patients on pre-existing continuous reno-renal therapy (CRRT) or intermittent hemodialysis (IHD

Primary outcomes:
measure: intracellular bacterial killing, assessed by number of colonies of bacterial growth following neutrophil exposure to bacteria and resistin
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hershey
country: United States
facility: Penn State Milton S Hershey Medical Center
state: Pennsylvania
Study officials:
affiliation: Penn State Milton S Hershey Med Ctr
name: Anthony Bonavia, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06209970: 35kDa Hyaluronan Fragment Treatment of Colorectal and Rectal Cancer
Official title: Injection of 35kDa Hyaluronan Fragment Alleviates Pain Associated With Radiotherapy for Treatment of Colorectal and Rectal Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer Pain
Keywords: 35kDa hyaluronan fragment
pain
colorectal cancer
rectal cancer
Lead sponsor: Nakhia Impex LLC
Sponsor class: INDUSTRY
First posted: 2024-01-18
Enrollment: 10
Sex: ALL
Minimum age (years): 48
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: HA35 (Bioactive HA or B-HA or HA35) have good tissue permeability (B-HA injection, Ministry of Health, Registration number L20200708MP07707). HA35 might not lose HA's bioactivities of binding to a variety of hyaluronan's binding proteins or receptors, including the analgesic and anticancer effects of hyaluronan, therefore being named bioactive HA or B-HA (10) (B-HA injection, Ministry of Health, Registration number L20200708MP07707).

Detailed description: The previous study has shown that naked mole rat who has high tissue content of hyaluronan and its fragments is insensitive to pain. The previous study has also shown that hyaluronan modulates pain-regulated TRPV1 channel opening, reducing peripheral nociceptor activity and pain. The previous study has again shown that local injection of 35kDa hyaluronan fragment HA35 is effective in treating inflammatory and neuropathic pain. This study employs freshly made HA35 injection for treatment of pain associated with radiotherapy for treatment of colorectal and rectal cancer. A numerical rating scale from 0 to 10 was used to assess the pain after 1 hour, 3 hours, 24 hours, 48 hours and 72 hours of the injection.

Eligibility criteria: Inclusion Criteria:

* All patients had different degrees of metastasis of the cancers, including bone metastasis.
* All patients undergo targeted radiotherapy shortly before this study.
* All the patient volunteers included in this study were allowed to use antibiotic compounds on and off during the treatment in order to prevent possible infection associated with the cancers for ethnic consideration.
* The included patients were aged 48 to 60 years.

Exclusion Criteria:

* Can not independently determine the level of pain.
* Severe bleeding and severe inflammation

Primary outcomes:
measure: Numerical Rating Scale
timeFrame: 1 hour, 3 hours, 24 hours, 48 hours and 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Qingdao
country: China
facility: Qingdao Huinorde Science and Technology Co.,Ltd
state: Shandong
Study officials:
References: